New data provides guidance for management of moderately dysplastic moles

October 26, 2018

Diagnosed more frequently in the United States than all other cancers combined, skin cancer will affect one in five Americans by the age of 70. Atypical moles - larger moles of irregular shape and color - can be challenging to examine and monitor given that they can mimic melanoma. Because patients with atypical moles are at an increased risk for melanoma, atypical moles with any suspicious features are often biopsied and given a grade describing the degree of abnormality. There is little data about clinical outcomes and the risk these moles pose long term, so no guidelines for management for dysplastic moles biopsied with positive histologic margins exist. Dermatologists are divided about the optimal management strategy; half of experts favor a second excision procedure and half prefer to monitor the biopsy site.

To address the lack of evidence, a national team of researchers within the Pigmented Lesion Subcommittee/Melanoma Prevention Working Group of the Eastern Cooperative Oncology Group/Southwestern Oncology Group led by chair, Caroline C. Kim, MD, in the Department of Dermatology at Beth Israel Deaconess Medical Center (BIDMC), examined outcomes of patients with moderately dysplastic moles that had been excisionally biopsied with positive histologic margins for a mean of nearly seven years. In all, out of 467 cases treated at nine U.S. academic medical centers, none went on to develop melanoma at the site of the excised mole; however, more than 22 percent of patients subsequently developed melanoma at a separate site. The findings, published in JAMA Dermatology on October 10, suggest that dysplastic moles - known by their Latin name "nevi" in medical terminology - are not necessarily precursors to melanoma, but rather, are a risk factor for melanoma.

"Our study is the largest study to date examining outcomes of moderately dysplastic nevi and carries significant clinical impact, as the insufficient quantity of prior data on outcomes and lack of clinical guidelines have led to much variability across the country in clinical management of these lesions," said Kim, who is director of BIDMC's Pigmented Lesion Clinic and Associate Professor of Dermatology at Harvard Medical School. "Our findings provide evidence that clinicians can move forward with close clinical observation rather than re-excision of moderately dysplastic nevi with positive margins. Our data also underscores the need for continued screening of patients with dysplastic nevi for future risk for melanoma."

The team plans to bolster their findings with future prospective studies that will include greater numbers of cases. In addition, Kim notes that BIDMC's Pigmented Lesion Clinic is one of only several clinics across the country using total body digital photography to monitor complex patients with atypical/dysplastic nevi, a technology Kim and colleagues will leverage as they continue to optimize patient care.
-end-
About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.

BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, MetroWest Medical Center, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit http://www.bidmc.org.

Beth Israel Deaconess Medical Center

Related Melanoma Articles from Brightsurf:

Boosting treatments for metastatic melanoma
University of Cincinnati clinician-scientist Soma Sengupta, MD, PhD, says that new findings from her and Daniel Pomeranz Krummel's, PhD, team might have identified a treatment-boosting drug to enhance effectiveness of therapies for metastatic cancer and make them less toxic, giving patients a fighting chance at survival and improved quality of life.

A promising new tool in the fight against melanoma
An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.

New targets for melanoma treatment
A collaborative study led by Monash University's Biomedicine Discovery Institute and the Olivia Newton-John Cancer Research Institute (ONJCRI) has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma.

Innovative smartphone-camera adaptation images melanoma and non-melanoma
An article published in the Journal of Biomedical Optics (JBO), ''Point-of-care, multispectral, smartphone-based dermascopes for dermal lesion screening and erythema monitoring,'' shows that standard smartphone technology can be adapted to image skin lesions, providing a low-cost, accessible medical diagnostic tool for skin cancer.

Antihistamines may help patients with malignant melanoma
Can a very common allergy medicine improve survival among patients suffering from the serious skin cancer, malignant melanoma?

Blood test for deadly eye melanoma
A simple blood test could soon become the latest monitoring tool for the early detection of melanoma in the eye.

Analysis of melanoma in US by age groups
This study used registry data to determine annual rates of melanoma in pediatric, adolescent, young adult and adult age groups, and the findings suggest an apparent decrease among adolescent and young adults between 2006 and 2015 but increases in older adults.

Vitamin D dials down the aggression in melanoma cells
Vitamin D influences the behaviour of melanoma cells in the lab by making them less aggressive, Cancer Research UK scientists have found.

B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.

Five things to know about melanoma
'Five things to know about ... melanoma' in CMAJ (Canadian Medical Association Journal) provides a brief overview of this malignant skin cancer for physicians and patients.

Read More: Melanoma News and Melanoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.